Buscar
Mostrando ítems 11-20 de 58
Estado del perfil de susceptibilidad in vitro de Enterobacterales frente a Ceftazidime/Avibactam
(Pontificia Universidad Javeriana, 2020)
Defining substrate specificity in the ctx-m family: The role of asp240 in ceftazidime hydrolysis
(American Society for Microbiology, 2018-06)
The natural diversification of CTX-M -lactamases led to the emergence of Asp240Gly variants in the clinic that confer reduced susceptibility to ceftazidime (CAZ). In this study, we compared the impact of this substitution ...
“Determinación de la eficacia de Ceftazidime/Avibactam por el método de microdilución en caldo en cepas de enterobacterias y de Pseudomonas aeruginosa recibidas en el INSPI, año 2017”
(PUCE-Quito, 2018)
Las enterobacterias y Pseudomonas aeruginosa son patógenos comúnmente relacionados con infecciones asociadas a la atención en salud, y de mayor relevancia clínica debido a la resistencia que presentan a los antibióticos. ...
Novos fármacos antibacterianos: uma abordagem química, biológica e perfis de resistência
(Florianópolis, SC, 2019)
Exploring the landscape of diazabicyclooctane (DBO) inhibition: Avibactam inactivation of PER-2 β-Lactamase
(American Society for Microbiology, 2017-06)
PER β -lactamases are an emerging family of extended-spectrum β -lactamases (ESBL) found in Gram-negative bacteria. PER β -lactamases are unique among class A enzymes as they possess an inverted omega (?) loop and extended ...
Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?
(American Society for Microbiology, 2017-04)
Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram-negative bacteria, we tested the efficacy of the combination of ceftazidime-avibactam (CAZ-AVI) with aztreonam (ATM) against carbapenem-resistant ...
Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
(2022)
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of ...
Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two blaKPC-2 gene copies without losing carbapenem resistance
(2022)
Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through ...
Estado del perfil de susceptibilidad in vitro de Enterobacterales frente a Ceftazidime/Avibactam
El creciente aumento en la resistencia bacteriana muchas veces asociado a mal uso o uso indiscriminado de los antibióticos, ha ocasionado que en los últimos años se presente un aumento en dicha resistencia lo que conlleva ...
Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two blaKPC-2 gene copies without losing carbapenem resistance
(2022)
Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through ...